Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Colorectal cancer

TNT and local recurrence in the RAPIDO trial — untangling the puzzle


Neoadjuvant chemotherapy offers a pragmatic alternative to the difficulties associated with delivering timely adjuvant chemotherapy in rectal cancer. Enthusiasm for administering neoadjuvant therapy to all patients with locally advanced rectal cancer is based on data from several phase III trials. Data from the RAPIDO trial are a critical component of this evidence.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Fragmentation of locally advanced rectal cancers following an extended delay between radiotherapy and surgery.


  1. Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open label, phase 3 trial. Lancet Oncol. 22, 29–42 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702–715 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. Jin, J. et al. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): the final reports. J. Clin. Oncol. 40, 1681–1692 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dijkstra, E. A. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery – a five-year follow-up of the RAPIDO Trial. Ann. Surg. (2023).

    Article  PubMed  Google Scholar 

  5. Ciseł, B. et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann. Oncol. 30, 1298–1303 (2019).

    Article  PubMed  Google Scholar 

  6. Liao, C. K. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol. 29, 3708–3727 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lefevre, J. H. et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J. Clin. Oncol. 34, 3773–3780 (2016).

    Article  PubMed  Google Scholar 

  8. Erlandsson, J., Pettersson, D., Glimelius, B., Holm, T. & Martling, A. Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy. Br. J. Surg. 106, 1248–1256 (2019).

    Article  CAS  PubMed  Google Scholar 

  9. Deidda, S. et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 156, 1141–1149 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jankowski, M. et al. Watch-and-wait strategy in rectal cancer: is there a tumour size limit? Results from two pooled prospective studies. Radiother. Oncol. 160, 229–235 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Robert Glynne-Jones.

Ethics declarations

Competing interests

R.G.-J. has acted as an advisor and/or consultant of Amgen and Incyte and has received honoraria for lectures from Servier and Johnson & Johnson. J.H. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glynne-Jones, R., Hollingshead, J. TNT and local recurrence in the RAPIDO trial — untangling the puzzle. Nat Rev Clin Oncol 20, 357–358 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing